Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
Users online: 2696  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page

Year : 2010  |  Volume : 55  |  Issue : 1  |  Page : 25-28
Impact of HLA-G in the outcome of vitiligo in Tunisian patients

1 Research Unit on the Antioxidant Compounds, Oxidative Stress, Trace Elements and Metabolic Diseases, Department of Physiology, Ecole Supérieure des Sciences et Techniques de la Santé de Tunis, Tunisia
2 Department of Dermatological and Venereal Diseases Hospital Foschi, Suresnes, Paris
3 Laboratory of Immunogenetics, Department of Immunology Research, France

Date of Web Publication4-Mar-2010

Correspondence Address:
Akrem Jalel
Ecole Supérieure des Sciences et Techniques de la Santé de Tunis. BP 176 Bab-Souika, 1006 Tunis, Tunisia

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5154.60346

Rights and Permissions


Background: The human leukocyte antigen (HLA) system in the skin coordinates the pigmentation and immune response and could be implicated in the pathogenesis of vitiligo. Human leukocyte antigen HLA-G is a nonclassic, major histocompatibility complex class I molecule expressed in the extravillous cytotrophoblast at the feto-maternal interface. It is known to protect the fetus from maternal cellular immunity. Analogically, it could be implicated in the pathogenesis of autoimmune diseases such as vitiligo. Aims: To compare the expression of HLA-G between vitiligo patients and healthy controls. Materials and Methods: In the present study, 22 vitiligo patients and 24 healthy controls were investigated to look for a possible correlation between HLA-G expression and this pathology. Expression of HLA-G in cutaneous biopsy specimens was investigated by immunohistochemical analysis. Results: HLA-G was detected in the biopsy specimens of 3 (13%) out of 22 patients. This number was significantly higher in healthy controls 18 (75%) out of 24 as compared to vitiligo patients ( P < 0.001). Conclusion: There is significant negative correlation between HLA-G expression and vitiligo. In our mind, upregulation of HLA-G expression in lesional skin could be local (superficial expression) or systemic (soluble HLA-G isoforms) compensation to restore normal pigmentation in lesions.

Keywords: Vitiligo, HLA-G, immune tolerogenesis

How to cite this article:
Jalel A, Ridha A, Laurent D, Philippe M, Hamdaoui M H. Impact of HLA-G in the outcome of vitiligo in Tunisian patients. Indian J Dermatol 2010;55:25-8

How to cite this URL:
Jalel A, Ridha A, Laurent D, Philippe M, Hamdaoui M H. Impact of HLA-G in the outcome of vitiligo in Tunisian patients. Indian J Dermatol [serial online] 2010 [cited 2022 Dec 5];55:25-8. Available from:

   Introduction Top

Vitiligo is an acquired cutaneous disorder that presents with gradual skin depigmentation produced by the deterioration of melanocyte functions. Several hypotheses have been proposed to explain the dysfunction and/or loss of melanocytes in the epidermis of vitiligo patients. [1],[2] These include an autoimmune mechanism, an auto-cytotoxic mechanism, and an abnormality in the melanocytes or in the surrounding keratinocytes producing factors, necessary for the survival and function of melanocytes. [3],[4],[5] Until now, the pathogenesis of vitiligo remains partially understood and probably involves various combinations of diverse mechanisms. The nonclassic human leukocyte antigen (HLA) class I molecule HLA-G, expressed on extravillous cytotrophoblasts at the feto-maternal interface during pregnancy, [6],[7] has been reported to play a role in mediating maternal tolerance of the fetal "semiallogeneic" graft. [8] This HLA-G antigen exhibits low polymorphism and can be expressed as both membrane-bound proteins (HLA-G1, HLA-G2, HLA-G3, HLA-G4) and soluble isoforms (HLA-G5, HLA-G6, HLA-G7). [9],[10] The soluble isoforms HLA-G5 and HLA-G6 have been detected in the amniotic fluid and serum of pregnant women. [11],[12] HLA-G expression was initially found to be restricted to the placenta. More recently, its expression has been detected in thymic epithelial cells, [13] various malignant cells, [14],[15],[16] and in peripheral blood monocytes, activated by IL-10. [17] HLA-G is known to inhibit the cytotoxic activity of T lymphocytes and natural killer cells (NK), [18],[19] which are essential effector cells in a melanocyte attack. [20] The purpose of the present study is to examine HLA-G expression in the lesional skin of vitiligo patients and in the skin of healthy controls.

   Materials and Methods Top

The study protocols and informed consent forms were approved by the Ethical Review Committee of the Medenine Hospital Centre (large area in the south of Tunisia). Informed consent was obtained from all participants. The patients and control subjects in the study were Tunisians. Unrelated patients with vitiligo (n = 22; 10 females; 12 males; age range 22-75 years) were included in the study. The mean age of vitiligo onset of the patients was 32.5 years and the mean duration of vitiligo was 16.5 years. Five patients had a family history of vitiligo. None of the patients included in the study had received any specific therapy in the previous three months. The clinical signs on which the diagnosis of vitiligo was based were characteristic loss of skin pigmentation with typical localization and white color on the skin lesions under Wood's lamp. The type of vitiligo was based on the extent of involvement and the distribution of pigmentation. The control group consisted of healthy volunteers (n = 24; 7 females; 17 males; age range 21 to 67 years) with no family history of vitiligo or other chronic dermatoses. One skin biopsy (Ø 3.5 mm) was obtained from each patient with vitiligo: One from the central part of the involved skin. Another skin biopsy (Ø 3.5 mm) was taken from the skin of healthy control subjects. All probands had skin phototype II (8 controls, 13 patients) or III (16 controls, 9 patients), Fitzpatrick classification. The biopsies were instantaneously stored at -808C until further use.

Laboratory investigation

Expression of the HLA-G molecule was analyzed by the immunohistochemical analysis of the cutaneous biopsy specimens. In addition to the biopsy specimens used for histopathological analysis and immunohistochemistry, control specimens were obtained from two human trophoblasts as a positive control. Monoclonal and polyclonal antibodies were used for the detection of HLA-G molecules in the biopsy specimens and serum of patients. monoclonal antibodies (mAbs) used were 87G IgG2a anti-HLA-G1 and -G5 (provided by D. Geraghty, Fred Hutchinson Cancer Research, Seattle, Washington), 4H84 IgG1 anti-denatured HLA-G heavy chain (provided by M. McMaster, University of California, San Francisco), and W6/32 IgG2a anti-HLA class I heavy chains associated with ß2m (Sigma, Milwaukee, Wisconsin). An isotype-matched antibody (Sigma) was used as the control. A rabbit polyclonal antibody PAG5-6 generated against the C-terminal peptide of the HLA-G α-chain encoded by intron 4 sequences was used to specifically recognize the soluble forms HLA-G5 and HLA-G6. [21]

Histology and immunohistochemistry

For histology, 4-µm-thick sections were obtained from each paraffin block and stained with hematoxylin and eosin. For immunohistochemical studies, 6-µm-thick sections of frozen tissues were fixed for 10 minutes in cold acetone, dehydrated, and permeabilized with saponine in phosphate buffered saline (PBS). Staining procedures were processed with the Dako Envision System (DAKO). Samples were incubated for 30 minutes in 50% human normal serum, in PBS, to eliminate nonspecific bindings. The samples were incubated with the following primary mAbs for 30 minutes: W6/32, 87G, 4H84 mAbs, and control antibody and followed by incubation with a secondary conjugated goat anti-mouse/antibody coupled with peroxidase (DAKO) for 30 minutes. After incubation for 10 minutes with a substrate, sections were counterstained with hematoxylin dye and mounted with antimounting medium (DAKO).

Statistical analysis

Data are presented as mean ± SEM. The Student's t test was used, and a value of P < 0.05 was considered significant.

   Results Top


For histology, 4-µm-thick sections were obtained from each paraffin block and stained with hematoxylin and eosin [Figure 1] and [Figure 2].

Expression of HLA-G in cutaneous biopsy specimens

Expression of HLA-G antigens in sections of vitiliginous cutaneous biopsy specimens was investigated through immunohistochemical analysis with the use of HLA-G mAbs: 87G IgG2a specific for HLA-G1 and HLA-G5 and 4H84 IgG1, which recognizes the α-1 domain (pan-HLA-G). Staining with W6/32 IgG2a was used to control the presence of intact HLA class I molecules in different tissues and was positive in all tested tissue biopsy specimens. We detected HLA-G proteins in 3 vitiligo patients. One patient specimen was positively stained by both 87G and 4H84 mAbs and two were positively stained by 4H84 mAb only. Trophoblasts used as positive controls exhibited strong staining with 87G and 4H84 mAbs, and skin biopsy specimens taken from healthy controls were also positively stained by 87G and 4H84 mAb.

   Discussion Top

In the skin, the potential role of the HLA system in pigmentation is not yet clarified, it's possible role in the pathogenesis of vitiligo as a depigmentation disorder remains unclear. The development of tolerance requires that the immune system utilize several strategies for neutralizing self-reactive T cells. These strategies include deletion, [22] anergy, [23] and immunoregulatory pathways. [24] This study suggests that the expression of HLA-G may be an alternative strategy to downregulate the acute immunoresponse against melanocytes. In vitro, soluble HLA-G has been demonstrated to induce apoptosis of activated CD8+ T cells [25] and to modulate NK [26] and allo-CTL response, [27] whereas, membrane-bound HLA-G proteins have been shown to inhibit both NK and T cell-mediated cytolysis, [8],[20] to suppress the proliferation of allospecific CD4+ T lymphocytes, [ 28] and to induce Th2 cytokine profile. [29] Interestingly, Graham and al., recently demonstrated that soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response. [30] In the present study, HLA-G expression was found in 13% of the 22 vitiligo patients. There was no case of extensive vitiligo between HLA-G-positive vitiligo patients. No significant difference between age, race, or sex could be detected between HLA-G-positive and HLA-G-negative patients. Therefore, the expression of HLA-G was likely deactivated during the process of vitiligo. It is possible that the suppression of melanin production deactivates HLA-G transcriptionally through negative feedback, to restore normal pigmentation. In melanocyte graft, HLA-G expression may allow escape from recognition and destruction of the melanocytes by alloreactive T cells. Furthermore, the soluble HLA-G forms, HLA-G5 and HLA-G6, may play an additional role in inhibiting the cytotoxic activity of NK cells. [31] Experimentally, numerous factors have been shown to upregulate HLA-G expression, such as IL-10. [32] An IL-10-HLA-G autocrine effect may contribute to melanocyte graft tolerance. However, we cannot exclude that HLA-G-positive patients may carry out specific HLA-G alleles associated with high HLA-G production. [33] The search for HLA-G expression in vitiligo patients could provide a new understanding of the factors implicated in vitiligo and a new modulation of immunosuppressive therapy in this pathology. For example, the use of soluble forms of HLA-G could contribute to immunosuppression and make it possible to reduce the amount of other immunosuppressive agents (corticoids and immunomodulators). The present study supports the hypothesis that negative HLA-G expression is associated with vitiligo. HLA-G expression seems to minimize active vitiligo. It remains to be understood why some vitiligo patients express HLA-G, whereas, other negative controls didn't develop vitiligo.

   References Top

1.Tobin DJ, Swanson NN, Pittelkow MR, Peters EM, Schallreuter KU. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000;191:407-16.  Back to cited text no. 1      
2.Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W. Review of the etiopathomechanism of vitiligo: A convergence theory. Exp Dermatol 1993;2:145-53.  Back to cited text no. 2      
3.Ongenae K, van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigm Cell Res 2003;16:90-100.  Back to cited text no. 3      
4.Schallreuter KU, Moore J, Wood JM, Beazley WD, Gaze DC, Tobin DJ, et al. In vivo and in vitro evidence for hydrogen peroxide (H 2 O 2 ) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 1999;pp 4:91-6.  Back to cited text no. 4      
5.Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, et al. New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. Pigm Cell Res 2002;15:87-92.  Back to cited text no. 5      
6.Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen HLA-G expressed in human trophoblasts. Science 1990;248:220-3.  Back to cited text no. 6      
7.McMaster MT, Librach CL, Zhou Y, Lim KH, Janatpour MJ, DeMars R, et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 1995;154:3771-8.  Back to cited text no. 7      
8.Rouas-Freiss N, Gonçalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997;94:11520-5.  Back to cited text no. 8      
9.Ishitani AG, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 1992;89:3947-51.  Back to cited text no. 9      
10.Fujii T, Ishitani A, Gerghty DE. A soluble form of HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol 1994;153:5516-24.  Back to cited text no. 10      
11.Hunt JS, Jadhav L, Chu W, Geraghty DE, Ober C. Soluble HLA-G circulates in maternal blood during pregnancy. Am J Obstet Gyneocol 2000;183:682-8.  Back to cited text no. 11      
12.Rebmann V, Pfeiffer K, Passler M, Ferrone S, Maier S, Weiss E, et al. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens 1999;53:14-22.  Back to cited text no. 12      
13.Crisa L, McMaster MT, Ishii JF, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997;186:289-98.  Back to cited text no. 13      
14.Paul P, Cabestré FA, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 1999;59:1954-60.  Back to cited text no. 14      
15.Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, et al. HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998;95:4510-5.  Back to cited text no. 15      
16.Wagner SN, Rebmann V, Willers CP, Grosse-Wilde H, Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 2000;356:220-1.  Back to cited text no. 16      
17.Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, et al. IL10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999;11:803-11.  Back to cited text no. 17      
18.Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha 1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cell: Is HLA-G the public ligand for natural killer inhibitory receptors? Proc Natl Acad Sci USA 1997;94:5249-54.  Back to cited text no. 18      
19.Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED. HLA-G2, -G3 and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK antigen-specific CTL cytolysis. J Immunol 2001;166:5018-26.  Back to cited text no. 19      
20.Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED. Implication of HLA-G molecule in heart-graft acceptance. Lancet 2000;355:2138.  Back to cited text no. 20      
21.Paul P, Cabestre FA, Ibrahim EC, Lefebvre S, Khalil-Daher I, Vazeux G, et al. Identification of HLA-G7 as a new splice variant of HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 2000;61:1138-49.  Back to cited text no. 21      
22.Nikolic B, Sykes M. Clonal deletion as a mechanism of transplantation tolerance. J Heart Lung Transplant 1996;15:1171-8.  Back to cited text no. 22      
23.Rocha B, Tanchot C, Von Boehmer H. Clonal energy blocks in vivo growth of mature T cells and can be reserved in the absence of antigen. J Exp Med 1993;177:1517-21.  Back to cited text no. 23      
24.Davies JD, Martin G, Phillips J, Marshall SE, Cobbold SP, Waldmann H. T cell regulation in adult transplantation tolerance. J Immunol 1996;157:529-33.  Back to cited text no. 24      
25.Fournel S, Aguerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, et al. Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000;164:6100-4.  Back to cited text no. 25      
26.Marchal-Bras Concalves R, Rouas-Freiss N, Connan F, Choppin J, Dausset J, Carosella ED, et al. A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc 2001;33:2355-9.  Back to cited text no. 26      
27.Kapasi K, Albert SE, Yie SM, Zavazava N, Librach CL. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 2000;101:191-200.  Back to cited text no. 27      
28.Bainbridge D, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4+ T-lymphocytes. J Reprod Immunol 2000;48:17-26.  Back to cited text no. 28      
29.Kanai T, Fujii T, Kozuma S, Yamashita T, Miki A, Kikuchi A, et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Hum Reprod 2001;7:195-200.  Back to cited text no. 29      
30.Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD41 T cells suppresses the allo-proliferative response: ACD41 T cell regulatory mechanism. Proc Natl Acad Sci USA 2001;98:12150-5.  Back to cited text no. 30      
31.Rebmann V, van Der Ven K, Pabler M, Pfeiffer K, Krebs D, Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 2001;57:15-21.  Back to cited text no. 31      
32.Thody AJ, Ridley K, Penny RJ, Chalmers R, Fisher C, Shuster S. MSH peptides are present in mammalian skin. Peptides 1983;4:813-6.  Back to cited text no. 32      
33.Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Aubock J. Vitiligo patients present lower plasma levels of alpha-melanotropin immunoreactivities. Neuropeptides 2006;40:177-83.  Back to cited text no. 33      


  [Figure 1], [Figure 2]

This article has been cited by
1 Association between exonic polymorphisms of human leukocyte antigen-G gene and non-segmental vitiligo in the Korean population
Su-Kang Kim, Hyo-Eun Kwon, Ki-Heon Jeong, Min Kyung Shin, Mu-Hyoung Lee
Indian Journal of Dermatology, Venereology and Leprology. 2022; 0: 1
[Pubmed] | [DOI]
2 Association between an HLA-G 14 bp insertion/deletion polymorphism and non-segmental vitiligo in the Korean population
K.-H. Jeong,S.-K. Kim,B.-K. Kang,J.-H. Chung,M.-K. Shin,M.-H. Lee
Archives of Dermatological Research. 2014;
[Pubmed] | [DOI]
3 Study of HLA-typing Class I in Patients Suffering from Vitiligo
S.B. Nejad,E. Khodaeiani,J. Majidi,A. Ghaffarzad,M. Goldust
Asian Journal of Biological Sciences. 2013; 6(6): 292
[Pubmed] | [DOI]
4 New insights into HLA-G and inflammatory diseases
Rizzo, R., Bortolotti, D., Baricordi, O.R., Fainardi, E.
Inflammation and Allergy - Drug Targets. 2012; 11(6): 448-463


Print this article  Email this article
   Next article
   Previous article 
   Table of Contents
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (798 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

    Materials and Me...
    Article Figures

 Article Access Statistics
    PDF Downloaded105    
    Comments [Add]    
    Cited by others 4    

Recommend this journal